AFT Pharmaceuticals 1H26 Result—Bloody Good Half
We believe the AFT investment case of: (1) strong, defensive, diversified medium-term ANZ earnings growth (five-year CAGR of ~+24%); and (2) long...
193 Views
AFT Pharmaceuticals — Making progress on growth strategy
AFT Pharmaceuticals has provided an investor update for Q2 CY25 (Q1 FY26), summarising material progress made across its global expansion and...
189 Views
AFT Pharmaceuticals — Setting the stage for sustained long-term growth
AFT Pharmaceuticals reported FY25 revenues of N Z$208m, posting a strong recovery in H2, with dissipating headwinds and traditional H2 seasonality...
271 Views
AFT Pharmaceuticals FY25 Result—Edging Ahead
AFT Pharmaceuticals' core ANZ business continues to perform strongly, with Australia being the highlight and margin expansion observed.
190 Views
The Overnight Report: Unconditional Surrender
All things considered, the reaction was fairly tame. ASX200 futures are looking at a softer open ahead of the Federal FOMC meeting tomorrow.
407 Views